Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed prostate cancer (all stages) for whom androgen deprivation therapy is indicated (except when indicated in a neoadjuvant/adjuvant therapy)~* Asymptomatic from prostate cancer~* Non-castrate level of testosterone (≥ 8 nmol/L (230 ng/dL)) at screening~* PSA ≥ 2 ng/mL at screening~Exclusion Criteria:~Has previously or is currently receiving:~* Hormonal therapy with intent to treat prostate cancer~* Systemic glucocorticoids~* Chemotherapy with the intent to treat prostate cancer~* Opiate analgesics for pain from prostate cancer~* Radiation therapy for treatment of the primary tumor or metastases~* Has history of known or suspected brain or skull metastases or leptomeningeal disease~* Has history of seizure including febrile seizure or any condition that may predispose to seizure or history of loss of consciousness or transient ischemic attack~* Clinically significant cardiovascular disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzalutamide (Type: EXPERIMENTAL): Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).